Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference
-
Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference
-
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit
-
Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit
-
Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
-
Companies with NDRs 5/19
-
Cantor Fitzgerald Starts Zynerba Pharmaceuticals (ZYNE) at Overweight
-
Zynerba Pharma (ZYNE) Prices 4.06M Offering of Common Stock at $8/Sh
-
Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Zynerba Pharma (ZYNE) Announces Proposed Common Share Offering
-
Zynerba Pharmaceuticals (ZYNE) Plans Public Offering of Common Stock
-
Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Pre-Open Movers 07/12: (ZGNX) (GLMD) (CA) Higher; (ZN) (ACRX) (AVGO) Lower (more...)
-
Pre-Open Movers 10/02: (RIGL) (SNCR) (TRN) Higher; (JWN) (GNW) (ROKU) Lower (more...)
-
UPDATE: Cantor Fitzgerald Upgrades Zynerba Pharmaceuticals (ZYNE) to Overweight
-
Morning Movers 8/14: (CVM) (NEFF) (EGLT) (FCAU) (ZYNE)
-
UPDATE: Cantor Fitzgerald Downgrades Zynerba Pharmaceuticals (ZYNE) to Neutral
-
Zynerba Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Zynerba Pharma (ZYNE) Prices 2.8M Shares at $18 Per Share
-
Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Cantor Fitzgerald Starts Zynerba Pharmaceuticals (ZYNE) at Overweight
-
Zynerba Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

